SYNLOGIC INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
SYNLOGIC INC. - More news...
SYNLOGIC INC. - More news...
- Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
- Synlogic to Present at the Oppenheimer 33rd Annual Healthcare Conference
- Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
- Synlogic Announces Participation in Upcoming Investor and Industry Conferences
- Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU)
- Synlogic Provides Corporate Update and Outlook for 2023
- Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development
- Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study
- Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update
- Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update
- Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3
- Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)
- Synlogic Reports Second Quarter 2022 Financial Results and Provides Business Update
- Synlogic Announces Second Quarter 2022 Conference Call and Webcast
- Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)
- Synlogic Announces Appointment of General Counsel and Corporate Secretary
- Synlogic to Present at the 2022 National PKU Alliance (NPKUA) Conference
- Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference
- Synlogic Reminds Stockholders of 2022 Annual General Meeting Details
- Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1618 for the Treatment of Phenylketonuria
- Synlogic Reports First Quarter 2022 Financial Results and Provides Business Update
- Synlogic Announces First Quarter 2022 Conference Call and Webcast
- Synlogic Announces Data Presentations at the 2022 Genetic Metabolic Dieticians International (GMDI) Conference and Garrod Symposium
- Synlogic Announces Data Presentations from Five Programs at the 2022 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference
- Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs at the Society for Inherited Metabolic Disorders 43rd Annual Meeting
- Synlogic Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
- Synlogic Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast
- Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer
- Synlogic To Present at Upcoming Investor and Industry Conferences
- Synlogic To Present at Upcoming Investor and Industry Conferences
